Efficacy, safety and pharmacokinetic study of a novel fentanyl-containing matrix transdermal patch system in Japanese patients with cancer pain

Clinical Drug Investigation

Volumn 28, Issue 5, 2008, Pages 313-325

  Miyazaki, Toyo ^a,h   Hanaoka, Kazuo ^b   Namiki, Akiyoshi ^c   Ogawa, Setsuro ^d   Kitajima, Toshimitsu ^e   Hosokawa, Toyoshi ^f   Ishida, Tomozo ^g   Nogami, Shoji ^g   Mashimo, Shigeto ^g  

^a Tokyo Clinic   (Japan)

^b JR Tokyo General Hospital   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g Janssen Pharmaceutical KK   (Japan)

^h Shin otemachi Building ^*  (Japan)

Author keywords

Cancer pain; Fentanyl, pharmacokinetics; Fentanyl, therapeutic use; Transdermal

Indexed keywords

FENTANYL; MORPHINE; OXYCODONE;

ADULT; AGED; ARTICLE; BLOOD DISEASE; CANCER PAIN; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INFESTATION; INSOMNIA; KIDNEY DISEASE; LABORATORY TEST; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SKIN IRRITATION; SOMNOLENCE; THORAX DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; VOMITING;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANALGESICS, OPIOID; ENDPOINT DETERMINATION; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEOPLASMS; OXYCODONE; PAIN; PAIN MEASUREMENT;

EID: 42049116778     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828050-00005     Document Type: Article

References (19)

1. Calis KA, Kohler DR, Corso DM. Transdermally administered fentanyl for pain management. Clin Pharmacol 1992; 11: 22-36
2. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997 Jan; 53 (1): 109-38
3. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000; 38: 59-89
4. US Food and Drug Administration. Public health advisory: safety warnings regarding use of fentanyl transdermal (skin) patches. July 15, 2005 [online]. Available from URL: http://www.fda.gov/cder/dr?g/advisory/fentanyl.htm [Accessed 2007 Sep 29]
5. Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother 1995 Oct; 29 (10): 969-71
6. Reeves MD, Ginifer CJ. Fatal intravenous misuse of transdermal fentanyl. Med J Aust 2002 Nov 18; 177 (10): 552-3
7. Kuhlman Jr JJ, McCaulley R, Valouch TJ, et al. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol 2003 Oct; 27 (7): 499-504
8. World Health Organization. Cancer pain relief. 2nd ed. Geneva: World Health Organization, 1996
9. Freynhagen R, von Giesen HJ, Busche P, et al. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage 2005; 30 (3): 289-97
10. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Ferney-Voltaire, France: World Medical Association Declaration of Helsinki, 1996
11. Marier JF, Lor M, Morin J, et al. Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Br J Clin Pharmacol 2007 Jan; 63 (1): 121-4
12. Marier JF, Lor M, Potvin D, et al. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 2006; 46: 642-53
13. Sathyan G, Guo C, Sivakumar K, et al. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005; 21 (12): 1961-8
14. Collins SL, Moore A, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 1997; 72: 95-7
15. Aubrun F, Hrazdilova O, Langeron O, et al. A high initial VAS score and sedation after IV morphine titration are associated with the need for rescue analgesia. Can J Anesth 2004; 51: 969-74
16. Mizuguchi T, Yamamura H, Takeda F, et al. Clinical evaluation of fentanyl patch (KJK-4263) for cancer pain. Part 1: examinations on safety, effectiveness and pharmacokinetics [in Japanese]. Med Drug J 2001; 37 (8): 2389-402
17. Mizuguchi T, Yamamura H, Takeda F, et al. Clinical evaluation of fentanyl patch (KJK-4263) for cancer pain. Part 2: switching and continuous administration based on morphine-fentanyl patch conversion chart [in Japanese]. Med Drug J 2001; 37 (8): 2403-26
18. Radbruch L, Sabatowski R, Petzke F, et al. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 2001; 15: 309-21
19. Tateishi T, Krivoruk Y, Ueng YF, et al. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996; 82: 167-72